| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1377071 | Inhibition of self-renewal of human HuH7 cells assessed as reduction in EpCAM positive fraction at 50 uM after 20 mins by propidium iodide staining-based flow cytometric analysis | 2017 | Journal of natural products, 06-23, Volume: 80, Issue:6
| Identification of BMI1 Promoter Inhibitors from Beaumontia murtonii and Eugenia operculata. |
| AID722695 | Cytotoxicity against human HL60 cells assessed as growth inhibition after 3 to 5 days by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
| Pharmacophore identification of c-Myc inhibitor 10074-G5. |
| AID1585072 | Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by prestoblue assay | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID1205236 | Inhibition of human recombinant His-tagged c-Myc-Max(S) heterodimer binding to DNA at 6.3 to 50 uM after 30 mins by SPR analysis in presence of biotinylated E-box-containing oligonucleotides | 2015 | Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
| Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. |
| AID1585082 | Inhibition of biotin-labeled EBOX oligonucleotide binding to GST-tagged Myc (368 to 454 residues)/His-tagged Max (23 to 102 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) at 500 uM incubated up to 600 secs by biolayer interferometry as | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID1205235 | Inhibition of heterodimerization of human recombinant His-tagged c-Myc-Max(S) compound treated for 20 mins with c-Myc and followed by added Max(S) at 6.3 to 50 uM after 30 mins by SPR analysis in presence of biotinylated E-box-containing oligonucleotides | 2015 | Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
| Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. |
| AID722700 | Inhibition of recombinant His6-tagged c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) (unknown origin) assessed as disruption of Myc-Max dimerization by electrophoretic mobility shift assay | 2013 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
| Pharmacophore identification of c-Myc inhibitor 10074-G5. |
| AID722702 | Binding affinity to human c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay | 2013 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
| Pharmacophore identification of c-Myc inhibitor 10074-G5. |
| AID722701 | Inhibition of recombinant His6-tagged c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) (unknown origin) assessed as disruption of Myc-Max dimerization at 100 uM by electrophoretic mobility shift assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
| Pharmacophore identification of c-Myc inhibitor 10074-G5. |
| AID1205266 | Induction of neutral lipid accumulation in human H460 cells assessed as ratio of mean florescent intensity of compound treated to control cells at 40 uM after 48 hrs by flow cytometry | 2015 | Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
| Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. |
| AID1585078 | Inhibition of full length Myc-Max (unknown origin) expressed in human PC3 cells at 12.5 to 25 uM after 24 hrs by luciferase reporter gene based mammalian two-hybrid assay | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID1585070 | Inhibition of Myc-Max (unknown origin) expressed in human LNCAP cells assessed as reduction in transcriptional activity at 25 uM after 1 day by luciferase reporter gene assay relative to control | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID1585081 | Inhibition of Myc-Max (unknown origin) expressed in human 22rv1 cells harboring UBE2C promoter assessed as reduction in ARV7 level at 12.5 to 25 uM after 48 hrs by Western blot analysis | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID1585080 | Inhibition of Myc-Max (unknown origin) expressed in human 22rv1 cells harboring UBE2C promoter assessed as reduction in ARV7 level after 1 day by luciferase reporter gene assay | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. |
| AID722694 | Cytotoxicity against human Daudi cells assessed as growth inhibition after 3 to 5 days by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
| Pharmacophore identification of c-Myc inhibitor 10074-G5. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |